FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2915662499> ?p ?o ?g. }

• W2915662499 endingPage "115" @default.
• W2915662499 startingPage "112" @default.
• W2915662499 abstract "Red blood cell (RBC) alloimmunization is more common in patients with sickle cell disease (SCD) than in any other studied patient population. The high prevalence of RBC alloimmunization is multi-factorial, likely involving the chronic hemolysis and inflammatory status of SCD itself, the transfusion burden of patients, and the RH genetic diversity of patients and blood donors, among other reasons. Antibody evanescence, or the decrease of RBC alloantibodies below levels detectable by blood bank testing, occurs frequently with fewer than 30% of alloantibodies estimated to be detected by current screening practices. Evanescence increases the likelihood that a patient with SCD will have a delayed hemolytic transfusion reaction upon future RBC exposure, with previously undetected alloantibodies coming roaring back in an anamnestic manner after exposure to the cognate RBC antigen. A subset of patients having delayed hemolytic transfusion reactions go on to experience hyperhemolysis; some but not all cases of hyperhemolysis are associated with previously evanescent RBC alloantibodies. There is an increasing appreciation of the association between RBC alloantibodies and RBC autoantibodies, as well as involvement of the alternative complement pathway in some instances of hyperhemolysis. A case report in this manuscript describes a highly alloimmunized patient with SCD who experiences a delayed hemolytic transfusion reaction with bystander hemolysis due to a previously evanescent, complement binding anti-M RBC alloantibody. Additional studies, including those involving multiple centers and countries, are needed to further understand RBC alloimmunization in patients with SCD and to develop strategies to prevent or mitigate potentially life-threatening hemolytic transfusion reactions. L’alloimmunisation anti-érythrocytaire post-transfusionnelle est plus fréquente au cours de la drépanocytose que dans d’autres pathologies. Cette prévalence élevée est d’origine multifactorielle avec notamment l’hémolyse chronique, le statut inflammatoire, le régime transfusionnel, le polymorphisme des groupes sanguins, et entre autres les variants RH. L’évanescence des anticorps, dans plus de 30 % des cas, représente une cause importante d’hémolyse post-transfusionnelle retardée (HPTR), par restimulation de ces anticorps non connus dans l’historique et indétectable avant la transfusion. De plus, il existe une fréquence non négligeable d’autoanticorps associés à des alloanticorps au cours de ces réactions transfusionnelles. Enfin, sur le plan des mécanismes la place de l’activation via la voie alterne du complément au cours de ces réactions semble jouer un rôle important. Dans ce manuscrit, nous décrivons un cas d’HPTR, avec hyperhémolyse, via un anti-M fixant le complément, et auyat présenté une évanescence. Des études à l’échelon international sont nécessaires pour comprendre les mécanismes d’alloimmunisation et l’implication des anticorps dans les HPTR." @default.
• W2915662499 created "2019-03-02" @default.
• W2915662499 creator A5001960825 @default.
• W2915662499 creator A5083730552 @default.
• W2915662499 date "2019-05-01" @default.
• W2915662499 modified "2023-09-30" @default.
• W2915662499 title "Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease" @default.
• W2915662499 cites W1590318774 @default.
• W2915662499 cites W1847157855 @default.
• W2915662499 cites W1884753074 @default.
• W2915662499 cites W1919720787 @default.
• W2915662499 cites W1927812827 @default.
• W2915662499 cites W1967118661 @default.
• W2915662499 cites W2000036073 @default.
• W2915662499 cites W2001528559 @default.
• W2915662499 cites W2003100159 @default.
• W2915662499 cites W2010071149 @default.
• W2915662499 cites W2026784781 @default.
• W2915662499 cites W2026891407 @default.
• W2915662499 cites W2035718279 @default.
• W2915662499 cites W2038522278 @default.
• W2915662499 cites W2087935695 @default.
• W2915662499 cites W2112154893 @default.
• W2915662499 cites W2142013648 @default.
• W2915662499 cites W2152440317 @default.
• W2915662499 cites W2156174439 @default.
• W2915662499 cites W2157729110 @default.
• W2915662499 cites W234508623 @default.
• W2915662499 cites W2460481123 @default.
• W2915662499 cites W2469084039 @default.
• W2915662499 cites W2470339002 @default.
• W2915662499 cites W2491380843 @default.
• W2915662499 cites W2514827382 @default.
• W2915662499 cites W2520469621 @default.
• W2915662499 cites W2553264212 @default.
• W2915662499 cites W2557398171 @default.
• W2915662499 cites W2606884609 @default.
• W2915662499 cites W2725345246 @default.
• W2915662499 cites W2742428030 @default.
• W2915662499 cites W2755621066 @default.
• W2915662499 cites W2763859108 @default.
• W2915662499 cites W2774247443 @default.
• W2915662499 cites W2801066337 @default.
• W2915662499 cites W2804186068 @default.
• W2915662499 cites W2884541117 @default.
• W2915662499 cites W2888542541 @default.
• W2915662499 cites W2900860724 @default.
• W2915662499 cites W4231784773 @default.
• W2915662499 doi "https://doi.org/10.1016/j.tracli.2019.02.003" @default.
• W2915662499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30857806" @default.
• W2915662499 hasPublicationYear "2019" @default.
• W2915662499 type Work @default.
• W2915662499 sameAs 2915662499 @default.
• W2915662499 citedByCount "18" @default.
• W2915662499 countsByYear W29156624992019 @default.
• W2915662499 countsByYear W29156624992020 @default.
• W2915662499 countsByYear W29156624992021 @default.
• W2915662499 countsByYear W29156624992022 @default.
• W2915662499 countsByYear W29156624992023 @default.
• W2915662499 crossrefType "journal-article" @default.
• W2915662499 hasAuthorship W2915662499A5001960825 @default.
• W2915662499 hasAuthorship W2915662499A5083730552 @default.
• W2915662499 hasConcept C111684460 @default.
• W2915662499 hasConcept C121857725 @default.
• W2915662499 hasConcept C126322002 @default.
• W2915662499 hasConcept C159654299 @default.
• W2915662499 hasConcept C163764329 @default.
• W2915662499 hasConcept C172680121 @default.
• W2915662499 hasConcept C203014093 @default.
• W2915662499 hasConcept C2776175824 @default.
• W2915662499 hasConcept C2776557347 @default.
• W2915662499 hasConcept C2777208419 @default.
• W2915662499 hasConcept C2778430493 @default.
• W2915662499 hasConcept C2778444020 @default.
• W2915662499 hasConcept C2779234561 @default.
• W2915662499 hasConcept C2779902561 @default.
• W2915662499 hasConcept C2780014101 @default.
• W2915662499 hasConcept C54355233 @default.
• W2915662499 hasConcept C71924100 @default.
• W2915662499 hasConcept C86803240 @default.
• W2915662499 hasConceptScore W2915662499C111684460 @default.
• W2915662499 hasConceptScore W2915662499C121857725 @default.
• W2915662499 hasConceptScore W2915662499C126322002 @default.
• W2915662499 hasConceptScore W2915662499C159654299 @default.
• W2915662499 hasConceptScore W2915662499C163764329 @default.
• W2915662499 hasConceptScore W2915662499C172680121 @default.
• W2915662499 hasConceptScore W2915662499C203014093 @default.
• W2915662499 hasConceptScore W2915662499C2776175824 @default.
• W2915662499 hasConceptScore W2915662499C2776557347 @default.
• W2915662499 hasConceptScore W2915662499C2777208419 @default.
• W2915662499 hasConceptScore W2915662499C2778430493 @default.
• W2915662499 hasConceptScore W2915662499C2778444020 @default.
• W2915662499 hasConceptScore W2915662499C2779234561 @default.
• W2915662499 hasConceptScore W2915662499C2779902561 @default.
• W2915662499 hasConceptScore W2915662499C2780014101 @default.
• W2915662499 hasConceptScore W2915662499C54355233 @default.
• W2915662499 hasConceptScore W2915662499C71924100 @default.
• W2915662499 hasConceptScore W2915662499C86803240 @default.

• next